Compare
Propanc Biopharma, Inc. vs PMGC Holdings Inc. vs Imunon, Inc. vs CalciMedica, Inc.
| Latest fiscal year | Propanc Biopharma, Inc. PPCB | PMGC Holdings Inc. ELAB | Imunon, Inc. IMNN | CalciMedica, Inc. CALC |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $590.1K | n/a | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | 31.4% | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$18.86M | -$7.75M | -$14.50M | -$29.56M |
| EPS (Diluted) | -$17.62 | n/a | -$6.83 | -$1.97 |
| Operating cash flow | -$5.68M | -$5.93M | -$13.90M | -$21.18M |
| Free cash flow | -$5.69M | -$6.38M | -$14.18M | -$21.21M |
| Cash & equivalents | n/a | n/a | $8.78M | $11.52M |
| Total assets | $12.78M | $12.87M | $12.29M | $13.59M |
| Total liabilities | $3.38M | $5.03M | $5.23M | $20.23M |
| Shareholders' equity | $9.40M | $7.84M | $7.06M | -$6.64M |
| Return on year-end equity | -200.6% | -98.9% | -205.3% | n/a |
| Shares outstanding | 3.31M | 80.7K | 3.42M | 15.44M |
Revenue, most recent five fiscal years
| Fiscal year | Propanc Biopharma, Inc. | PMGC Holdings Inc. | Imunon, Inc. | CalciMedica, Inc. |
|---|---|---|---|---|
| Latest | n/a | $590.1K Ended 2025-12-31 | $500.0K Ended 2022-12-31 | n/a |
| 1 year earlier | n/a | n/a | $500.0K Ended 2021-12-31 | n/a |
| 2 years earlier | n/a | $1.71M Ended 2023-12-31 | $500.0K Ended 2020-12-31 | n/a |
| 3 years earlier | n/a | $766.3K Ended 2022-12-31 | $500.0K Ended 2019-12-31 | n/a |
| 4 years earlier | n/a | n/a | $500.0K Ended 2018-12-31 | n/a |